ArticleEClinicalMedicine2024

Safety, immunogenicity, and efficacy of a modified COVID-19 mRNA vaccine, SW-BIC-213, in healthy people aged 18 years and above: a phase 3 double-blinded, randomized, parallel controlled clinical trial in Lao PDR (Laos).

Yi Fang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.